

Sophie Piperno-Neumann

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2353900/sophie-piperno-neumann-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93
papers

3,523
citations

31
h-index

58
g-index

103
ext. papers

4,628
ext. citations

7.4
avg, IF

4.71
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 93 | SF3B1 mutations are associated with alternative splicing in uveal melanoma. <i>Cancer Discovery</i> , 2013 , 3, 1122-1129 | 24.4 | 282 |
| 92 | Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. <i>Nature Communications</i> , 2016 , 7, 10615 | 17.4 | 223 |
| 91 | Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 93-97 | 13.4 | 191 |
| 90 | Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1732-1742 | 21.7 | 141 |
| 89 | Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). <i>Journal of Clinical Oncology</i> , 2018 , 36, 1232-1239 | 2.2 | 135 |
| 88 | Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 120-133 | 21.7 | 134 |
| 87 | Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. <i>International Journal of Cancer</i> , 2014 , 134, 1207-13 | 7.5 | 129 |
| 86 | Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1070-1080 | 21.7 | 120 |
| 85 | Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. <i>Clinical Cancer Research</i> , 2010 , 16, 2352-62 | 12.9 | 120 |
| 84 | Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2797-802 | 2.2 | 117 |
| 83 | Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases 2009 , 50, 2572-80 | | 107 |
| 82 | Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 446-455 | 21.7 | 92 |
| 81 | Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. <i>European Journal of Cancer</i> , 2014 , 50, 1137-47 | 7.5 | 85 |
| 80 | Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. <i>British Journal of Ophthalmology</i> , 2014 , 98, 769-74 | 5.5 | 80 |
| 79 | CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies from the French OS2006 phase 3 trial. <i>Clinical Immunology</i> , 2017 , 167, 118-128 | 7.2 | 80 |
| 78 | Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. <i>European Journal of Cancer</i> , 2017 , 83, 125-131 | 7.5 | 79 |
| 77 | Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. <i>Molecular Oncology</i> , 2014 , 8, 1508-20 | 7.9 | 71 |

| | | | |
|----|--|------|----|
| 76 | Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 457-64 | 21.7 | 70 |
| 75 | Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015 , 51, 742-50 | 7.5 | 70 |
| 74 | Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 1263-1272 | 21.7 | 69 |
| 73 | Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 312-9 | 21.7 | 67 |
| 72 | Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. <i>Nature Communications</i> , 2018 , 9, 1866 | 17.4 | 65 |
| 71 | Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. <i>Clinical Cancer Research</i> , 2012 , 18, 3934-41 | 12.9 | 63 |
| 70 | Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021 , 385, 1196-1206 | 59.2 | 63 |
| 69 | Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 639-648 | 21.7 | 47 |
| 68 | Phase-II trials in osteosarcoma recurrences: A systematic review of past experience. <i>European Journal of Cancer</i> , 2017 , 75, 98-108 | 7.5 | 45 |
| 67 | Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. <i>Oncotarget</i> , 2016 , 7, 33542-56 | 3.3 | 38 |
| 66 | Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. <i>European Journal of Cancer</i> , 2018 , 88, 57-66 | 7.5 | 38 |
| 65 | Patient-derived xenografts recapitulate molecular features of human uveal melanomas. <i>Molecular Oncology</i> , 2013 , 7, 625-36 | 7.9 | 37 |
| 64 | Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases. <i>Journal of Pathology: Clinical Research</i> , 2018 , 4, 227-240 | 5.3 | 36 |
| 63 | Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. <i>PLoS ONE</i> , 2014 , 9, e80836 | 3.7 | 34 |
| 62 | Evolutionary Routes in Metastatic Uveal Melanomas Depend on Alterations. <i>Clinical Cancer Research</i> , 2019 , 25, 5513-5524 | 12.9 | 31 |
| 61 | Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group. <i>American Journal of Ophthalmology</i> , 2016 , 168, 217-226 | 4.9 | 29 |
| 60 | So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020. <i>Cancers</i> , 2019 , 11, | 6.6 | 28 |
| 59 | Therapeutic options in metastatic uveal melanoma. <i>Developments in Ophthalmology</i> , 2012 , 49, 166-181 | | 28 |

| | | | |
|----|---|-----|----|
| 58 | Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. <i>Oncologist</i> , 2016 , 21, 281-2 | 5.7 | 27 |
| 57 | Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9030-9030 | 2.2 | 27 |
| 56 | Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTCS (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). <i>BMC Cancer</i> , 2015 , 15, 854 | 4.8 | 21 |
| 55 | Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. <i>European Journal of Cancer</i> , 2015 , 51, 202-9 | 7.5 | 20 |
| 54 | PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma. <i>Cancers</i> , 2019 , 11, | 6.6 | 19 |
| 53 | The off-label use of targeted therapies in sarcomas: the OUTCS program. <i>BMC Cancer</i> , 2014 , 14, 870 | 4.8 | 19 |
| 52 | Bone sarcomas: from biology to targeted therapies. <i>Sarcoma</i> , 2012 , 2012, 301975 | 3.1 | 19 |
| 51 | Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts. <i>Pigment Cell and Melanoma Research</i> , 2017 , 30, 317-327 | 4.5 | 18 |
| 50 | A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1541-1549 | 2.9 | 17 |
| 49 | Upcoming translational challenges for uveal melanoma. <i>British Journal of Cancer</i> , 2015 , 113, 1249-53 | 8.7 | 16 |
| 48 | Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. <i>European Journal of Cancer</i> , 2020 , 124, 152-160 | 7.5 | 16 |
| 47 | Selumetinib-based therapy in uveal melanoma patient-derived xenografts. <i>Oncotarget</i> , 2018 , 9, 21674-21686 | 3.9 | 15 |
| 46 | Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. <i>BMJ Open</i> , 2019 , 9, e025877 | 3 | 14 |
| 45 | Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1031-1039 | 6.1 | 14 |
| 44 | Protein Tyrosine Phosphatase 4A3 (PTP4A3) Promotes Human Uveal Melanoma Aggressiveness Through Membrane Accumulation of Matrix Metalloproteinase 14 (MMP14) 2016 , 57, 1982-90 | | 14 |
| 43 | Development of a Prognostic Nomogram for Liver Metastasis of Uveal Melanoma Patients Selected by Liver MRI. <i>Cancers</i> , 2019 , 11, | 6.6 | 13 |
| 42 | The biological and prognostic significance of angiotropism in uveal melanoma. <i>Laboratory Investigation</i> , 2017 , | 5.9 | 12 |
| 41 | Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas. <i>Modern Pathology</i> , 2019 , 32, 1786-1794 | 9.8 | 12 |

| | | | |
|----|---|------|----|
| 40 | Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival. <i>JAMA Ophthalmology</i> , 2020 , 138, 182-188 | 3.9 | 11 |
| 39 | Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. <i>International Journal of Cancer</i> , 2020 , 146, 413-423 | 7.5 | 10 |
| 38 | Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018 , 99, 28-36 | 7.5 | 9 |
| 37 | A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9502-9502 | 2.2 | 9 |
| 36 | Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020 , 9, 172-182 | 2.2 | 9 |
| 35 | Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. <i>American Journal of Roentgenology</i> , 2020 , 215, 1539-1548 | 5.4 | 9 |
| 34 | Splicing Patterns in -Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neopeptides. <i>Cancer Discovery</i> , 2021 , 11, 1938-1951 | 24.4 | 9 |
| 33 | Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2018 , 23, 948-955 | 5.7 | 9 |
| 32 | Diffusion-weighted MRI for uveal melanoma liver metastasis detection. <i>European Radiology</i> , 2015 , 25, 2263-73 | 8 | 8 |
| 31 | Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1818-1827 | 3.1 | 8 |
| 30 | Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11053-11053 | 7.2 | 7 |
| 29 | ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 479, 2-11 | 5.1 | 7 |
| 28 | Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years. <i>International Journal of Cancer</i> , 2019 , 145, 2135-2143 | 7.5 | 6 |
| 27 | Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11574-11574 | 2.2 | 6 |
| 26 | Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. <i>Cancers</i> , 2021 , 13, | 6.6 | 5 |
| 25 | Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. <i>Cancers</i> , 2019 , 11, | 6.6 | 4 |
| 24 | Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11508-11508 | 2.2 | 4 |
| 23 | First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. <i>Anticancer Research</i> , 2017 , 37, 1403-1407 | 2.3 | 4 |

| | | | |
|----|--|------|---|
| 22 | PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11507-11507 | 2.2 | 4 |
| 21 | Metastatic uveal melanoma: The final frontier.. <i>Progress in Retinal and Eye Research</i> , 2022 , 101041 | 20.5 | 3 |
| 20 | Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1693-1699 | 3.1 | 3 |
| 19 | Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , 2021 , 21, 631 | 4.8 | 3 |
| 18 | Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , 2021 , 150, 108-118 | 7.5 | 3 |
| 17 | Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. <i>Bulletin Du Cancer</i> , 2021 , 108, 163-176 | 2.4 | 3 |
| 16 | Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study. <i>BMC Cancer</i> , 2017 , 17, 419 | 4.8 | 2 |
| 15 | Randomized phase II trial of trofosamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11507-11507 | 2.2 | 2 |
| 14 | Post-cross-over activity of regorafenib (RE) in soft tissue sarcoma: Analysis from the REGOSARC trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11052-11052 | 2.2 | 2 |
| 13 | Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?. <i>Cancers</i> , 2021 , 13, | 6.6 | 2 |
| 12 | Overall survival benefit from tebentafusp in patients with best response of progressive disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9509-9509 | 2.2 | 2 |
| 11 | Undifferentiated endometrial sarcomas (UES): Results of a French sarcoma group (FSG) retrospective series of 52 patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e17109-e17109 | 2.2 | 1 |
| 10 | Benefit of intensified perioperative chemotherapy within high-risk CINSARC patients with resectable soft tissue sarcomas (CIRSARC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS11078-TPS11078 | 2.2 | 1 |
| 9 | Prognostic impact of pulmonary nodules diagnosed at initial presentation in patients with osteosarcoma.. <i>Pediatric Blood and Cancer</i> , 2022 , e29725 | 3 | 1 |
| 8 | Helping Patients Communicate With Oncologists When Cancer Treatment Resistance Occurs to Develop, Test, and Implement a Patient Communication Aid: Sequential Collaborative Mixed Methods Study.. <i>JMIR Research Protocols</i> , 2022 , 11, e26414 | 2 | |
| 7 | Rare bone sarcoma: A retrospective analysis of 149 adult patients from the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11523-11523 | 2.2 | |
| 6 | A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11506-11506 | 2.2 | |
| 5 | Prognosis of desmoid tumors (DT): A prospective nationwide survey of 771 patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11047-11047 | 2.2 | |

| | | |
|---|--|-----|
| 4 | Expression and prognostic significance of PDGF ligands (A, B, C, and D) and PDGFR (A, B, and L) in soft-tissue sarcomas and GIST.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11067-11067 | 2.2 |
| 3 | Weekly paclitaxel (WP) +/- bevacizumab (B) in angiosarcoma (AS) patients (pts): Analysis of prognostic/predictive factors from a randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11024-11024 | 2.2 |
| 2 | REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and non-chordomas).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS11576-TPS11576 | 2.2 |
| 1 | Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome. <i>Scientific Reports</i> , 2021 , 11, 23429 | 4.9 |